Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Pregabalin abuse among opiate addicted patients.

Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D.

Eur J Clin Pharmacol. 2013 Dec;69(12):2021-5. doi: 10.1007/s00228-013-1578-5. Epub 2013 Aug 30.

PMID:
23989299
2.

Pregabalin Abuse amongst Opioid Substitution Treatment Patients.

McNamara S, Stokes S, Kilduff R, Shine A.

Ir Med J. 2015 Nov-Dec;108(10):309-10.

PMID:
26817289
3.

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.

Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P.

Eur J Clin Pharmacol. 2010 Sep;66(9):947-53. doi: 10.1007/s00228-010-0853-y. Epub 2010 Jun 19.

PMID:
20563568
4.
5.

Potential for pregabalin abuse or diversion after past drug-seeking behavior.

Filipetto FA, Zipp CP, Coren JS.

J Am Osteopath Assoc. 2010 Oct;110(10):605-7.

PMID:
21068226
6.

[Pregabalin--a drug with abuse potential?].

Skopp G, Zimmer G.

Arch Kriminol. 2012 Jan-Feb;229(1-2):44-54. German.

PMID:
22448469
7.

[Pregabalin for the reduction of opiate withdrawal symptoms].

Kämmerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D.

Psychiatr Prax. 2012 Oct;39(7):351-2. doi: 10.1055/s-0032-1305042. Epub 2012 Jun 11. German.

PMID:
22689280
8.

Pregabalin abuse and dependence in Germany: results from a database query.

Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C.

Eur J Clin Pharmacol. 2013 Jun;69(6):1335-42. doi: 10.1007/s00228-012-1464-6. Epub 2013 Jan 5.

PMID:
23292158
9.

Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.

Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Jul;35(6):357-9.

PMID:
21740692
10.

Pregabalin dependence: a case report.

Halaby A, Kassm SA, Naja WJ.

Curr Drug Saf. 2015;10(2):184-6.

PMID:
25336156
11.

The pain of pregabalin prescribing in prisons.

Bicknell M.

Br J Gen Pract. 2013 Aug;63(613):405. doi: 10.3399/bjgp13X670615. No abstract available.

12.

Factors associated with pregabalin dispensing at higher than the approved maximum dose.

Bodén R, Wettermark B, Brandt L, Kieler H.

Eur J Clin Pharmacol. 2014 Feb;70(2):197-204. doi: 10.1007/s00228-013-1594-5. Epub 2013 Oct 19.

PMID:
24141597
13.

Pregabalin in clinical psychiatry and addiction: pros and cons.

Martinotti G.

Expert Opin Investig Drugs. 2012 Sep;21(9):1243-5. doi: 10.1517/13543784.2012.703179. Epub 2012 Jun 24.

PMID:
22725618
14.

Clinical pharmacokinetics of pregabalin in healthy volunteers.

Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL.

J Clin Pharmacol. 2010 Aug;50(8):941-50. doi: 10.1177/0091270009352087. Epub 2010 Feb 10.

PMID:
20147618
15.

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.

Zacny JP, Paice JA, Coalson DW.

Pharmacol Biochem Behav. 2012 Jan;100(3):560-5. doi: 10.1016/j.pbb.2011.10.023. Epub 2011 Nov 4.

16.

Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?

Guay DR.

Am J Geriatr Pharmacother. 2005 Dec;3(4):274-87. Review.

PMID:
16503325
17.

Pregabalin abuse after past substance-seeking behavior.

Papazisis G, Garyfallos G, Sardeli C, Kouvelas D.

Int J Clin Pharmacol Ther. 2013 May;51(5):441-2. doi: 10.5414/CP201881.

PMID:
23547854
18.

Pregabalin: an antiepileptic agent useful for neuropathic pain.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2007 Jul 15;64(14):1475-82. Review.

PMID:
17617497
19.

Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.

Saldaña MT, Pérez C, Navarro A, Masramón X, Rejas J.

Clin Drug Investig. 2012 Jun 1;32(6):401-12. doi: 10.2165/11599400-000000000-00000.

PMID:
22480279
20.

The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview.

Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, De Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M.

Curr Pharm Des. 2013;19(35):6367-74. Review.

PMID:
23782139

Supplemental Content

Support Center